Skip to content

Daniel F. Levey

3 papers in the library · publishing 2026

Papers

Sort Most recent Most cited

769. Can the genetic of liver enzyme involved in THC metabolism tell us who are the cannabis users at greater risk of psychosis?

International Journal of Neuropsychopharmacology September 9, 2026 M Di Forti, I Austin-Zimmerman, E Spinazzola et al.

Abstract Background Epidemiological data have consistently shown an association between heavy cannabis use and increased risk of psychotic disorders. Nevertheless, not all cannabis users develop the illness. Evidence from other substance of abuse such as Alcohol suggest how genetic differences in enzymes involved in its metabolism influence individual response to the drug. No studies to data...

Genetic Pathways Point to the Biology Underlying the Association Between Cannabis Use Disorder and Psychosis

Biological Psychiatry Global Open Science May 13, 2026 I. Austin-Zimmerman, Qiang Li, E. Johnson et al.

Background Cannabis use is associated with increased risk of psychotic disorders, but the underlying biological mechanisms remain unclear. We used genetic data to investigate the molecular pathways contributing to the association between cannabis use disorder (CUD) and psychosis. Methods We conducted a cross-disorder meta-analysis of genome-wide association studies (GWASs) on schizophrenia and...

Genomic Variation Predicts Real-Time Δ 9 -tetrahydrocannabinol Response in Humans

Uri Bright, Suhas Ganesh, Daniel F. Levey et al.

Abstract Background Cannabis is one of the most widely used psychoactive substances worldwide. Δ 9 -tetrahydrocannabinol (Δ 9 -THC) is the main contributor to cannabis-induced effects such as euphoria, anxiety, and psychotomimetic effects, and is metabolized by several hepatic enzymes, including CYP3A4. There are interindividual differences in how cannabis affects users, which have substantial...